



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/645,215		
		Filing Date	August 21, 2003		
		First Named Inventor	Guenther Adolf		
		Art Unit	1642		
		Examiner Name	Huff, Sheela Jitendra		
Sheet	1	of	2	Attorney Docket Number	1/1383

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SSH		ROBERT J. KREITMAN; Targeted Therapies - First International Congress; Vol. 5 No. 10 Pages 949-954 October 2002; Pharma Press Ltd ISSN 1369-7056	
SSH		RANDOLPH D. CHRISTEN ET AL; In Vitro Modulation of Cisplatin Accumulation in Human Ovarian Carcinoma Cells by Pharmacologic Alteration of Microtubules; J. of Clinical Investigation Vol. 92 No. 1 pages 431-440 July 1993; The American Society for Clinical Investigation, Inc.	
SSH		IRA S. JAFFREY; Response to Maytansine in a Patient with Malignant Thymoma; Cancer Treatment Reports Vol. 64 No. 1 pages 193-194 January 1980; Palisades Oncology Associates, Pomona, N.Y.	
SSH		GEDSKE DAUGAARD; The Effect of Chemotherapy in the treatment of Malignant Thymoma; Thymic Tumors 1987 pages 112-119 (Karger, Basel 1989) 7th Cancer Research Workshop, Genoble ISSN 3-8055-4800-1	
SSH		BENJAMIN DREWINKO ET AL; Differential Killing Efficacy of Twenty Antitumor Drugs on Proliferating and Nonproliferating Human Tumor Cells; Cancer Research Vol. 41 No. 6 pages 2328-2333 June 1981; ISSN 0008-5472	
SSH		K. WATANABE ET AL; Possible Role of Calmodulin Sensitivity of Anti Neoplastic Agents; Federation Proceedings Vol. 42 No. 3 page 361 (1983); 67 Annual Meetings of the Federation of American Societies for experimental Biology, Chicago, IL. No. 4109	
SSH		SARAJANE ROSS ET AL; Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate; Cancer Research Vol. 62 No. 9 pages 2546-2553 May 1, 2002; Issn 0008-5472	
SSH		MARC M. MAREEL ET AL; Effects of Microtubule Inhibitors on Invasion and on Related Activities of Tumor Cells; International Review of Cytology Vol. 90 pages 125-168 (1984); International Review of Cytology, Academic Press, New York Issn 0074-7596	
		C. LIU ET AL; Cure of human colon cancer xenografts by a C242-maytansinoid conjugate; Proceedings of the American Association for Cancer Research Annual Meeting Vol. 36 page 407 Abstract No. 2428. Fifth annual meeting of the American association for cancer research, Canada	
SSH		P. KOPF-MAIER ET AL; Changes in the Cytoskeleton Pattern of Tumor Cells by Cisplatin in Vitro; Chemico-Biological Interactions Vol. 82 No. 3 pages 295-316 (1992); Issn 0009-2797	

Examiner Signature		Date Considered	1/31/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/645,215
				Filing Date	August 21, 2003
				First Named Inventor	Guenther Adolf
				Art Unit	1642
				Examiner Name	Huff, Sheela Jitendra
				Attorney Docket Number	1/1383
Sheet	2	of	2		

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	1/31/05
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.